Kidney Cell Therapy

About LyGenesis

LyGenesis is developing a revolutionary cell therapy platform that uses lymph nodes as in vivo bioreactors to grow functional ectopic organs, potentially solving the critical supply-demand imbalance in organ transplantation. Its most advanced program is a Phase 2a trial for end-stage liver disease, with proof-of-concept data also established for thymus (aging), kidney, and pancreas (Type 1 diabetes) indications. The company's technology, founded on pioneering research by Dr. Eric Lagasse, could dramatically reduce the cost, complexity, and risk of treating organ failure, representing a paradigm shift in regenerative medicine.

Therapeutic Areas